Bill Ackman Has Made Over $2.2 Billion On A Deal That's Arguably A Failure

Irish pharmaceutical company Actavis buying Allergan for for $US219 per share in a cash and stock deal valued at $US66 billion.

For months, Allergan has worked to fend off a hostile bid from Canadian pharmaceutical company Valeant and activist investor Bill Ackman.

All of Ackman and Valeant’s offers had been rejected. The most recent bid for the Botox-maker was $US53 billion.

Even though Valeant was unsuccessful in its takeover attempt, Ackman is still getting a massive payout.

Ackman, who runs Pershing Square Capital, last held 28,878,538 shares of Allergan, according to his fund’s most recent 13F filing.

Since he first disclosed his stake back in April, shares of Allergan have surged.

According to our calculations, Ackman has made more than $US2.28 billion on his position in Allergan. He started buying Allergan stock back in February, so it’s probably even higher.

Ackman doesn’t own any shares of Valeant.

Meanwhile, Ackman recently disclosed a large stake in animal health company Zoetis.

Zoetis is seen as a potential takeover target. Shares of Zoetis were last trading up more than 2.10% on Monday.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.